Phathom Pharmaceuticals (PHAT) Cost of Revenue (2023 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Cost of Revenue of $15.1 million for Q2 2026, up 199.64% year-over-year from $5.0 million in Q2 2025, and up 25.84% quarter-over-quarter from $12.0 million in Q1 2026.
Phathom Pharmaceuticals (PHAT) Cost of Revenue (2023 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Cost of Revenue for 4 consecutive years, with $15.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cost of Revenue rose 199.64% year-over-year to $15.1 million; the TTM figure through Jun 2026 stood at $40.9 million (up 174.09% YoY), while the FY2025 annual figure was $22.6 million, up 183.44% from the prior year.
- Cost of Revenue improved to $15.1 million in Q2 2026 per PHAT's latest filing, from $12.0 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $15.1 million in Q2 2026 and bottomed at $167000.0 in Q4 2023.
- Historically, Cost of Revenue has averaged $5.3 million across 4 years, with a median of $3.8 million in 2024.
- Annual changes were most pronounced in 2024 — Cost of Revenue jumped 2184.43% — and 2025, when it jumped 100.47%.
- Phathom Pharmaceuticals' Cost of Revenue stood at $167000.0 in 2023, then surged by 2184.43% to $3.8 million in 2024, then jumped by 100.47% to $7.6 million in 2025, then jumped by 97.38% to $15.1 million in 2026.
- Business Quant data shows PHAT's Cost of Revenue at $15.1 million in Q2 2026, $12.0 million in Q1 2026, and $7.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn | 15.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.10 Mn |
| Jun 30, 2026 | 15.10 Mn |
| Mar 31, 2026 | 12.00 Mn |
| Mar 31, 2026 | 12.00 Mn |
| Dec 31, 2025 | 7.65 Mn |
| Dec 31, 2025 | 7.65 Mn |
| Sep 30, 2025 | 6.19 Mn |
| Sep 30, 2025 | 6.19 Mn |
| Jun 30, 2025 | 5.04 Mn |
| Jun 30, 2025 | 5.04 Mn |
| Mar 31, 2025 | 3.72 Mn |
| Mar 31, 2025 | 3.72 Mn |
| Dec 31, 2024 | 3.82 Mn |
| Dec 31, 2024 | 3.82 Mn |
| Sep 30, 2024 | 2.36 Mn |
| Sep 30, 2024 | 2.36 Mn |
| Jun 30, 2024 | 1.38 Mn |
| Jun 30, 2024 | 1.38 Mn |
| Mar 31, 2024 | 426,000.00 |
| Mar 31, 2024 | 426,000.00 |